Literature DB >> 10428730

T-cell-rich large-B-cell lymphoma (TCRBCL) as compared to diffuse large-B-cell lymphoma.

J J Oudejans, D F Dukers, R L ten Berge, C J Meijer.   

Abstract

Entities:  

Mesh：

Year:  1999        PMID： 10428730      PMCID： PMC1866675          DOI： 10.1016/s0002-9440(10)65126-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


× No keyword cloud information.
  5 in total

1.  Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma.

Authors:  R L ten Berge; D F Dukers; J J Oudejans; K Pulford; G J Ossenkoppele; D de Jong; J F Miseré; C J Meijer
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

2.  Cytolytic (TIA-1+) tumor infiltrating lymphocytes in B cell non-Hodgkin's lymphomas. SWOG Central Repository Members.

Authors:  J Diaz; R Tubbs; M Stoler; T Grogan
Journal:  Leuk Lymphoma       Date:  1993-01

3.  Activated cytotoxic T cells as prognostic marker in Hodgkin's disease.

Authors:  J J Oudejans; N M Jiwa; J A Kummer; G J Ossenkoppele; P van Heerde; J W Baars; P M Kluin; J C Kluin-Nelemans; P J van Diest; J M Middeldorp; C J Meijer
Journal:  Blood       Date:  1997-02-15       Impact factor: 22.113

4.  T-cell-rich large-B-cell lymphomas contain non-activated CD8+ cytolytic T cells, show increased tumor cell apoptosis, and have lower Bcl-2 expression than diffuse large-B-cell lymphomas.

Authors:  R E Felgar; K R Steward; J B Cousar; W R Macon
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

5.  T-cell-rich B-cell lymphomas: diagnosis and response to therapy of 44 patients.

Authors:  J P Greer; W R Macon; R E Lamar; S N Wolff; R S Stein; J M Flexner; R D Collins; J B Cousar
Journal:  J Clin Oncol       Date:  1995-07       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.